{
}
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton highlights the stock's attractiveness in the European pharmaceutical sector, noting it is trading at a significant discount compared to peers. Anticipation builds for share buyback announcements at the end of January.
Sanofi, Europe's largest pharmaceutical group, generates 70.6% of its net sales from pharmaceuticals, focusing on specialty and general medicine. Human vaccines account for 17.4%, while consumer health products make up 12%. Geographically, 43% of sales come from the U.S., with 5.5% from France and 18.6% from Europe.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicines accounting for 59.3%. Human vaccines contribute 17.4%, while consumer healthcare products make up 12%. By the end of 2023, the company will operate 54 production sites globally, with significant sales in the U.S. (43%) and Europe (18.6%).
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton views Sanofi's stock as highly attractive within the European pharmaceutical sector as it trades at a significant discount compared to peers, anticipating share buyback announcements at the end of January.
Regeneron Pharmaceuticals, Inc. focuses on developing and selling drugs for eye and inflammatory diseases and cancer. Its net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. The company has around 35 products in clinical development as of the end of 2022.
The J.P. Morgan Healthcare Conference's second day featured presentations from GSK, Novartis, Sanofi, and Eli Lilly, following a day of significant deal announcements and financial overviews from major biopharma companies. As the first day concluded, attendees faced protests accusing the industry of prioritizing profits over lives, amid heightened police presence due to recent events, including the killing of UnitedHealthcare CEO Brian Thompson. Despite the protests, conference participants remained largely unaffected.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
Roche has entered a $1 billion deal with Innovent Biologics for the DLL3-targeted ADC IBI3009, following promising data from Zai Lab's DLL3 ADC in small cell lung cancer. AstraZeneca faces scrutiny in China, potentially impacting operations, while Viatris received an FDA warning letter for its Indian plant, affecting 11 products. In other developments, Ideaya Biosciences is paying $75 million for rights to SHR-4849, and Hutchmed is divesting its interest in a traditional medicine unit to focus on ADCs.
Merck & Co. is shifting its focus from TIGIT and LAG-3 inhibitors to a subcutaneous version of Keytruda and a PD-1x/VEGF bispecific, while entering the obesity market with a preclinical GLP-1 receptor agonist from Hansoh Pharma for $112 million. Sanofi reported promising mid-stage results for its TL1A antibody duvakitug in inflammatory bowel disease, achieving significant remission rates, while Vertex Pharmaceuticals faced setbacks with its NaV1.8 inhibitor suzetrigine in chronic pain trials. Novo Nordisk completed a $16.5 billion acquisition of Catalent to address supply issues for semaglutide, despite ongoing shortages, while Novartis announced the closure of two MorphoSys sites, affecting 330 employees, following an $800 million write-down on pelabresib.
Novartis is closing MorphoSys sites in Munich and Boston, resulting in approximately 330 layoffs, as part of its integration strategy following the €2.7 billion acquisition earlier this year. The decision aligns with a focus on prioritizing R&D programs, particularly the delayed approval pathway for the oncology candidate pelabresib. This trend of post-acquisition job cuts has been observed across several major pharma companies in recent years.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains buy rating for Sanofi with target price of 115 euros
09:41 23.01.2025
sanofi maintains strong market position with diverse product portfolio and global reach
09:29 23.01.2025
sanofi's diverse portfolio drives strong sales across global markets
09:27 23.01.2025
ubs maintains buy rating for sanofi with target price of 115 euros
09:27 23.01.2025
regeneron pharmaceuticals faces downgrade as it focuses on diverse drug portfolio
13:02 16.01.2025
protests mark conclusion of j p morgan healthcare conference day two
16:12 14.01.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
biopharma deals and challenges emerge in asia with focus on adc developments
VBI Vaccines Inc.
Shanghai Pharmaceuticals Holding Co., Ltd
Hoffmann-La Roche AG
Lonza Group AG
AstraZeneca PLC
I-Mab
SK bioscience Co.,Ltd.
Zai Lab Ltd
IDEAYA Biosciences, Inc.
Brii Biosciences Ltd.
HUTCHMED
Sanofi
BeiGene, Ltd.
Innovent Biologics, Inc.
Viatris Inc.
Cytokinetics, Incorporated
CHN
IND
Yong Ying-I
Pascal Soriot
Show more
14:37 03.01.2025
merck shifts focus to biotech and obesity as keytruda exclusivity looms
United States Dollar
Sanofi
Vertex Pharmaceuticals Inc
Merck & Co., Inc.
Catalent, Inc.
Novartis AG
Novo Nordisk A/S
USA
Show more
04:47 20.12.2024
Novartis to close MorphoSys sites and lay off 330 employees
Euro
Sanofi
GSK plc
Gilead Sciences, Inc.
Incyte Corp
Novartis AG
Immunomedics Inc.
Horizon Therapeutics Public Lim
Bellus Health Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Co
Amgen Inc.
MorphoSys AG
USA
DEU
CHE
Vas Narasimhan
Show more
15:47 19.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Cryptocurrency Trends
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Central Banks and Digital Currencies
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Banking Regulations
Central Bank Actions
Retail and Consumer Goods
Private Equity Deals
Global Financial Events
Government Economic Policies
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
People: